Roche Reviewing Next Steps For Lebrikizumab After Mixed Phase III Data
This article was originally published in The Pink Sheet Daily
Executive Summary
One of two identical Phase III trials testing the IL-13 blocker in severe asthma patients met its primary endpoint, while the other failed.